In contrast, we have previously found that there is high aberrant expression of either MerTK or Axl in all grades of astrocytic tumors tested, and that co-expression of MerTK and Axl was present in all high grade gliomas and glioblastoma patient samples [15], additionally sequence analysis found no receptor mutations (unpublished data). This evidence concerns the gene AXL and central nervous system cancer.